West Pharmaceutical Opens Second Manufacturing Plant in China - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

West Pharmaceutical Opens Second Manufacturing Plant in China



Untitled Document

West Pharmaceutical Services, a provider of solutions for injectable-drug administration, started up its compression-molding plant in the Shanghai Zhangjiang High-Tech Industrial Development Zone Qingpu Park in China. The new plant is adjacent to West’s injection-molding facility that was dedicated in September 2009.

The 11,900-m2 compression-molding plant manufactures components used for packaging injectable drugs, supplying customers primarily in China and the Asia-Pacific region. Construction began in June 2011.

In addition to the plants in Qingpu, West’s presence in the Asia-Pacific region includes a factory in Singapore and sales offices in Australia, China, India and Singapore. The company’s first manufacturing facility in India is under construction.

Source: West Pharmaceutical Services

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here